Showing results (151-160 of 298) with videos related to

Sort By:
Pageof 30
Pulmonary Circulation|August 23, 2017
Differential IL-1 signaling induced by BMPR2 deficiency drives pulmonary vascular remodelingJosephine Pickworth, Alexander Rothman, James Iremonger, et al.
Arthritis and Rheumatism|July 9, 2003
Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouseVoon H Ong, Lowri A Evans, Xu Shiwen, et al.
American Journal of Respiratory and Critical Care Medicine|August 27, 2011
A novel murine model of severe pulmonary arterial hypertensionLoredana Ciuclan, Olivier Bonneau, Martin Hussey, et al.
Hypertension (Dallas, Tex. : 1979)|April 16, 2014
Endothelial apoptosis in pulmonary hypertension is controlled by a microRNA/programmed cell death 4/caspase-3 axisKevin White, Yvonne Dempsie, Paola Caruso, et al.
The European Respiratory Journal|October 27, 2022
Genetic counselling and testing in pulmonary arterial hypertension: a consensus statement on behalf of the International Consortium for Genetic Studies in PAHChristina A Eichstaedt, Catharina Belge, Wendy K Chung, et al.
Circulation|March 25, 2014
Proteomic analysis implicates translationally controlled tumor protein as a novel mediator of occlusive vascular remodeling in pulmonary arterial hypertensionJessie R Lavoie, Mark L Ormiston, Carol Perez-Iratxeta, et al.
The Journal of Clinical Investigation|April 3, 2008
An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertensionGeorg Hansmann, Vinicio A de Jesus Perez, Tero-Pekka Alastalo, et al.
Pulmonary Circulation|July 28, 2026
Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art ReviewSudarshan Rajagopal, Joseph Abueg, Kevin M Hart, et al.
Thorax|February 9, 2007
Demographic features, BMPR2 status and outcomes in distal chronic thromboembolic pulmonary hypertensionJay Suntharalingam, Rajiv D Machado, Linda D Sharples, et al.
Pulmonary Circulation|May 11, 2013
Anticipated classes of new medications and molecular targets for pulmonary arterial hypertensionNicholas W Morrell, Stephen L Archer, Albert Defelice, et al.
Pageof 30